Induction of CYP2E1 activity in liver transplant patients as measured by chlorzoxazone 6-hydroxylation

Clinical Pharmacology and Therapeutics

Volumn 63, Issue 3, 1998, Pages 296-302

  Burckart, Gilbert J ^a,b   Frye, Reginald F ^a   Kelly, Patrick ^a   Branch, Robert A ^a   Jain, Ashok ^a   Fung, John J ^a   Starzl, Thomas E ^a   Venkataramanan, Raman ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORZOXAZONE; CYTOCHROME P450;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; ENZYME ACTIVATION; ENZYME ACTIVITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL;

ADULT; AGED; CASE-CONTROL STUDIES; CHLORZOXAZONE; CYTOCHROME P-450 CYP2E1; ENZYME INDUCTION; FEMALE; HUMANS; HYDROXYLATION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; TIME FACTORS;

EID: 0031942094     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90161-8     Document Type: Article

References (25)

1. Venkataramanan R, Habucky K, Burckart GJ, Ptachcinski RJ. Clinical pharmacokinetics in organ transplant patients. Clin Pharmacokinet 1989;16: 134-61.
2. Yang CS, Smith T, Ishizaki H, Hong JY. Enzyme mechanisms in the metabolism of nitrosamines. IARC Sci Publ 1991;105:265-74.
3. Yang CS, Yoo JS, Ishizaki H, Hong JY. Cytochrome P450IIE1: roles in nitrosamine metabolism and mechanisms of regulation. Drug Metab Rev 1990;22:147-59.
4. Koop DR. Oxidative and reductive metabolism by cytochrome P450 2E1. FASEB J 1992;6:724-30.
5. Guengerich FP, Kim DH, Iwasaki M. Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 1991;4:168-79.
6. Raucy JE, Lasker JM, Lieber CS, Black M. Acetaminophen activation by human liver cytochromes P450 IIE1 and P450 IA2. Arch Biochem Biophys 1989;271: 270-83.
7. Zand R, Nelson SD, Slattery JT, Thummel KE, Kalhorn TF, Adams SP, et al. Inhibition and induction of cytochrome P4502E1-catalyzed oxidation by isoniazid in humans. Clin Pharmacol Ther 1993;54:142-9.
8. Kivisto KT, Kroemer HK. Use of probe drugs as predictors of drug metabolism in humans. J Clin Pharmacol 1997;37:40S-8S.
9. Kharasch ED, Thummel KE, Mhyre J, Lillibridge JH. Single-dose disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P450 2E1. Clin Pharmacol Ther 1993;53:643-50.
10. Peter R, Bocker R, Beaune PH, Iwasaki M, Guengerich FP, Yang CS. Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem Res Toxicol 1990;3:566-73.
11. Yamazaki H, Guo Z, Guengerich FP. Selectivity of cytochrome P4502E1 in chlorzoxazone 6-hydroxylation. Drug Metab Dispos 1995;23:438-40.
12. Kim RB, Yamazaki H, Chiba K, O'Shea D, Mimura M, Guengerich FP, et al. In vivo and in vitro characterization of CYP2E1 activity in Japanese and Caucasians. J Pharmacol Exp Ther 1996;279:4-11.
13. Frye RF, Matzke GR, Adedoyin A, Schade RR, Branch RA. Effect of liver disease on CYP activity assessed utilizing a cocktail approach [abstract]. Pharm Res 1995;12:S380.
14. Starzl TE, Iwatsuki S, Esquivel CO, Todo S, Kam I, Lynch S, et al. Refinements in the surgical technique of liver transplantation. Semin Liver Dis 1985;5:349-56.
15. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16: 31-41.
16. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60: 646-9.
17. Frye RF, Matzke GR, Adedoyin A, Porter JA, Branch RA. Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes. Clin Pharmacol Ther 1997;62:365-76.
18. Frye RF, Stiff DD. Determination of chlorzoxazone and 6-hydroxychlorzoxazone in human plasma and urine by high-performance liquid chromatography. J Chromatogr B Biomed Appl 1996;686:291-6.
19. Adedoyin A, Li P, Brickner, S, Cain J. Decreased metabolism of chlorzoxazone in microsomes from bile duct ligated rats. In: Proceedings of the Eleventh International Symposium on Microsomes and Drug Oxidations. Los Angeles; 1996. p. 170.
20. Abdel-Razzak Z, Loyer P, Fautrel A, Gautier J, Corcos L, Turlin B, et al. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol 1993;44:707-15.
21. Tindberg N, Baldwin HA, Cross AJ, Ingelmansundberg M. Induction of cytochrome P450 2E1 in rat and gerbil astrocytes by inflammatory factors and ischemic injury. Mol Pharmacol 1996;50:1065-72.
22. Frye RF, Matzke GR, Palevsky P, Rault R. Impaired 6-hydroxychlorzoxazone elimination in patients with renal insufficiency: implication for pharmacogenetic studies [abstract]. Clin Pharmacol Ther 1996;59:168.
23. Kelly PA, Frye RF, Burckart GJ, Lever J, Venkataramanan RV, Fung JJ, et al. Differential CYP450 isozyme activity following orthotopic liver transplantation [abstract]. Clin Pharmacol Ther 1996;59:136.
24. Bendriss A, Bechtel Y, Paintaud G, Bendriss EK, Joanne C, Bresson-Hadni S, et al. Stability of debrisoquine (CYP2D6) phenotype in liver transplant patients. Ther Drug Monit 1995;17:113-9.
25. Venkataramanan R, Kalp K, Rabinovitch M, Cuellar R, Ptachcinski RJ, Teperman L, et al. Conjugative drug metabolism in liver transplant patients. Transplant Proc 1989;21:2455.